Christina Tartaglia

Akero Therapeutics, founded in 2017 and headquartered in South San Francisco, pioneers novel therapies for serious metabolic diseases, focusing on Efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH). EFX, an Fc-FGF21 fusion protein, has shown potential in reducing liver fat and inflammation, reversing fibrosis, and improving insulin sensitivity and lipids.